Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Q: I have Type 2 diabetes, and my doctor insists that I give up beverages with almost all sugar substitutes and stick with water. Can you explain what’s wrong with ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

On July 16 2025, the Court of Appeal dismissed AstraZeneca’s appeal and upheld the first instance decision, finding that AstraZeneca’s compound ...

Dapagliflozin delivers cardiometabolic benefits in patients with myocardial infarction, regardless of their baseline A1c ...

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

Chandigarh: Type 2 diabetes mellitus (T2DM) may not be invincible after all. Researchers are exploring the possibility of ...

A new study published in The New England Journal of Medicine showed that daily dapagliflozin dramatically reduced the risk of ...

The Maryland Prescription Drug Affordability Board (PDAB) found that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) present affordability ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

This drug combo gives doctors and patients a new way to manage diabetes over the long term. It offers stable blood sugar control, helps with weight loss, and lowers blood pressure—all without causing ...